Elenjickal Elias John
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elenjickal Elias John has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Suceena Alexander
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India
5 shared publications Anna T. Valson
Department of Renal Medicine, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
4 shared publicationsAthul Thomas
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India
4 shared publicationsSantosh Varughese
Department of Nephrology, Christian Medical College and Hospital, Vellore, India
4 shared publicationsNisha Jose
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India
3 shared publicationsSabina Yusuf
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India
3 shared publications
Latest Publications
- 15 September 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (11) , 1693-1708
Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease
Background and Objectives Canagliflozin is an orally active, selective, reversible sodium-glucose cotransport-2 (SGLT-2) inhibitor used in patients with chronic kidney disease (CKD) to prevent cardiovascular (CV) events and CKD progression. Its initiation is currently not recommended in advanced CKD [estimated glomerular filtration rate (eGFR) < 20 mL/min per 1.73 m2], end-stage kidney disease, or in those on kidney replacement therapies due to insufficient clinical and safety data. This study aimed to develop a population pharmacokinetic (popPK) model using data from patients with advanced CKD, including those on maintenance hemodialysis (HD), to characterize the steady-state pharmacokinetics (PK) of canagliflozin at 100 mg and 300 mg doses, and to assess the impact of significant covariates on its PK. Methods PK data were obtained from a single-center, prospective, single-arm, open-label interventional study conducted in two cohorts. The first cohort was a detailed PK sampling done in 10 patients receiving intermittent HD for at least 3 months and the second cohort included sparse PK sampling in 13 patients with advanced CKD, not yet on dialysis. Canagliflozin PK parameters were modeled using nonlinear mixed-effects modeling (NONMEM® version 7.5) with the first-order conditional estimation method with interaction. Model performance was evaluated using goodness of fit plot, bootstrap (n = 1000), and normalized prediction distribution error (NPDE). Model-based simulations were performed using the final model to predict concentration–time profiles at steady state, evaluate the impact of significant covariates on predicted steady-state area under the curve (AUC), and compare PK profiles between patients with non-dialysis CKD and those with hemodialysis. Results A total of 332 PK observations from 23 patients were analyzed. The mean age of the cohort was 67 ± 15 years with a mean body mass index of 27 ± 5 kg/m2. A two-compartment popPK model of canagliflozin with lag-time, sequential zero- and first-order absorption, and first-order elimination was developed. Age was a significant covariate of the absorption rate constant (Ka), which increased with age. Sex was a significant covariate for the apparent volume of distribution (V/F), which was lower in women (80.7 L in men and 49.1 L in women). Model-based simulations demonstrated that steady-state AUC was 66% higher in women compared with men. Additionally, AUC increased approximately threefold in both sexes when the canagliflozin dose was escalated from 100 mg to 300 mg. Notably, eGFR was not a determinant of steady state exposure. Conclusions The developed model demonstrates that steady state canagliflozin exposure is higher in women and with use of higher dose, whereas eGFR does not meaningfully alter drug exposure in patients with advanced CKD. Model-based simulations support the potential use of canagliflozin in HD patients and highlight the need for further evaluation of dose optimization strategies in this high-risk population. Trial Registration The trials were registered at Clinicaltrials.gov (NCT05309785).
- 15 September 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (11) , 1693-1708
Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease
Background and Objectives Canagliflozin is an orally active, selective, reversible sodium-glucose cotransport-2 (SGLT-2) inhibitor used in patients with chronic kidney disease (CKD) to prevent cardiovascular (CV) events and CKD progression. Its initiation is currently not recommended in advanced CKD [estimated glomerular filtration rate (eGFR) < 20 mL/min per 1.73 m2], end-stage kidney disease, or in those on kidney replacement therapies due to insufficient clinical and safety data. This study aimed to develop a population pharmacokinetic (popPK) model using data from patients with advanced CKD, including those on maintenance hemodialysis (HD), to characterize the steady-state pharmacokinetics (PK) of canagliflozin at 100 mg and 300 mg doses, and to assess the impact of significant covariates on its PK. Methods PK data were obtained from a single-center, prospective, single-arm, open-label interventional study conducted in two cohorts. The first cohort was a detailed PK sampling done in 10 patients receiving intermittent HD for at least 3 months and the second cohort included sparse PK sampling in 13 patients with advanced CKD, not yet on dialysis. Canagliflozin PK parameters were modeled using nonlinear mixed-effects modeling (NONMEM® version 7.5) with the first-order conditional estimation method with interaction. Model performance was evaluated using goodness of fit plot, bootstrap (n = 1000), and normalized prediction distribution error (NPDE). Model-based simulations were performed using the final model to predict concentration–time profiles at steady state, evaluate the impact of significant covariates on predicted steady-state area under the curve (AUC), and compare PK profiles between patients with non-dialysis CKD and those with hemodialysis. Results A total of 332 PK observations from 23 patients were analyzed. The mean age of the cohort was 67 ± 15 years with a mean body mass index of 27 ± 5 kg/m2. A two-compartment popPK model of canagliflozin with lag-time, sequential zero- and first-order absorption, and first-order elimination was developed. Age was a significant covariate of the absorption rate constant (Ka), which increased with age. Sex was a significant covariate for the apparent volume of distribution (V/F), which was lower in women (80.7 L in men and 49.1 L in women). Model-based simulations demonstrated that steady-state AUC was 66% higher in women compared with men. Additionally, AUC increased approximately threefold in both sexes when the canagliflozin dose was escalated from 100 mg to 300 mg. Notably, eGFR was not a determinant of steady state exposure. Conclusions The developed model demonstrates that steady state canagliflozin exposure is higher in women and with use of higher dose, whereas eGFR does not meaningfully alter drug exposure in patients with advanced CKD. Model-based simulations support the potential use of canagliflozin in HD patients and highlight the need for further evaluation of dose optimization strategies in this high-risk population. Trial Registration The trials were registered at Clinicaltrials.gov (NCT05309785).
- 26 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (6) , 788-809
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD
Key Points: Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD. The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events. The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events. Background: The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR 2, has not been adequately studied. Methods: We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (2). Results: A total of ten randomized controlled trials were included (total of 4800 patients with eGFR 2). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR 2 (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and ≥30 ml/min per 1.73 m2 (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR 2 (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR ≥30 ml/min per 1.73 m2, SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms. Conclusions: SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.
- 26 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (6) , 788-809
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD
Key Points: Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD. The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events. The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events. Background: The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR 2, has not been adequately studied. Methods: We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (2). Results: A total of ten randomized controlled trials were included (total of 4800 patients with eGFR 2). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR 2 (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and ≥30 ml/min per 1.73 m2 (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR 2 (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR ≥30 ml/min per 1.73 m2, SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms. Conclusions: SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.
- Open Access
- 11 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1531748
Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease
Diabetic kidney disease (DKD) is a global health problem and is an important risk factor for kidney failure and cardiovascular (CV) disease (Alicic et al., 2017). Until recently, renin angiotensin-aldosterone system inhibitors (RAASi) were the only available agents with proven renoprotective benefit (Brenner et al., 2001;Lewis et al., 2001). In 2019, sodium glucose co-transporter-2 inhibitors (SGLT-2i) revolutionized the management of DKD with added cardiovascular and renal benefits (Perkovic et al., 2019;Heerspink et al., 2020;EMPA-KIDNEY Collaborative Group, 2023). The last few years have been promising with the discovery of newer therapies in DKD targeting diverse pathophysiologic pathways (Heerspink et al., 2019;Bakris et al., 2020;Perkovic et al., 2024). Despite these existing therapies, there is a substantial residual risk of kidney disease progression (Figure 1).The pathogenesis of DKD, though initiated by a metabolic disturbance is perpetuated by multiple interlinked pathways involving the hemodynamic, inflammatory, oxidative, and fibrotic systems (Tuttle et al., 2022). This Research Topic aims to understand these complex mechanisms, identify newer therapeutic targets, and test these agents in well designed clinical trials. Eight articles were published in this Research Topic [retrospective studies (2), animal studies (2), meta-analysis (2), clinical trial (1), and in-depth review (1)]. The in-depth review by Zhang et al., summarizes the proposed mechanisms of albuminuria, the current progress, and the future directions of therapeutic avenues in DKD.Current practice guidelines recommend withholding SGLT-2i during critical illness requiring hospitalization ("sick day rules") (Watson et al., 2023). However, in a multicenter retrospective cohort study of adults hospitalized with acute heart failure associated AKI, exposure to SGLT-2i during AKI was associated with no difference in time to renal recovery, but a lower 30-day mortality (Aklilu et al., 2023). Whether these findings can be generalized to all other etiologies of AKI is unknown. In this Research Topic, Alcantar-Vallin et al. explore the role of continuing or initiating SGLT-2i during an AKI episode. This was a retrospective cohort study involving 374 patients hospitalized with AKI, of whom 58 received SGLT-2i treatment during the hospitalization. The authors found that SGLT-2i use was not associated with risk of major adverse kidney events but was associated with a reduced risk of mortality (OR 0.08, 95% CI 0.01-0.64).In the FLOW trial, semaglutide, a glucagon like peptide-1 receptor agonist (GLP-1Ra) was shown to decrease clinically relevant kidney outcomes and death from CV causes in patients with type 2 diabetes and CKD (Perkovic et al., 2024). In a post hoc analysis of this trial, the benefits of semaglutide in reducing kidney outcomes were found to be consistent in participants with and without SGLT-2i use (Mann et al., 2024). In this Research Topic Cao et al. carried out a head-to-head comparison of GLP-1Ra and SGLT-2i in patients with DKD. This was a randomized, open-label, non-inferiority trial. A total of 106 patients with type 2 diabetes and CKD were randomized 1:1 to receive either polyethylene glycol loxenatide (PEG-Loxe) 0.2 mg subcutaneous once weekly or dapagliflozin 10 mg orally once daily for 24 weeks. The primary outcome was change in urine albumin creatinine ratio (UACR) from baseline to 24 weeks. The authors showed that following 24 weeks of treatment there was no difference in change in UACR between the two groups (mean intergroup difference 1.7% (95% CI, -3 to 6.5%, p=0.380).Diabetes is a state of oxidative stress and inflammatory burden, which contributes to complications including diabetic nephropathy. The heightened oxidative stress in diabetes is multi-factorial, viz., activation of polyol and hexosamine pathways, accumulation of glycolysis intermediates, activation of protein kinase C, mitochondrial dysfunction, etc. (Jin et al., 2023). There is a strong mutually enhancing interaction between inflammation and oxidative stress. Pro-inflammatory cytokines and chemokines activate reactive oxygen species (ROS) leading to macrophage activation, resulting in more oxidative stress. In return, ROS induce the expression of pro-inflammatory cytokines by activating transcription factors like nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1) (Caturano et al., 2023). Hence addressing oxidative stress and inflammation as potential therapeutic targets for DKD have assumed greater significance (Winiarska et al., 2021). In recent years, Chinese herbal medicines have been reported to attenuate progression of DKD by their anti-inflammatory and anti-oxidative properties (Zhong et al., 2015). Chen et al. identified 16 potentially renoprotective Chinese herbal medicines for DKD (PRCHMDKD) which were known to target multiple oxidative stress pathways. The authors then retrospectively analyzed the National Health Insurance Database of Taiwan from 2000 to 2017. They identified 43,480 PRCHMDKD users with DKD and 1,442 PRCHMDKD users with advanced DKD who were matched with an equal number of non-users using a nearest neighbour approach. PRCHMDKD use was associated with reduction in adjusted hazard ratios for kidney failure, all-cause-and CV mortality in the overall and advanced DKD population.Huangkui capsule (HKC) is a traditional Chinese medicine which is currently approved for treatment of CKD in China. It is made from an ethanol extract of Abelmoschus Manihot flowers (Li et al., 2021). In a multicentre, double blind, placebo-controlled randomized clinical trial (RCT) conducted in China, the combination of irbesartan + HKC was found to significantly reduce albuminuria at 24 weeks as compared to irbesartan alone (Zhao et al., 2022). In this Research Topic, Tan et al. carried out a systematic review and meta-analysis of English and Chinese databases to include RCTs comparing HKC combined with RAASi...
- 11 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1531748
Open AccessEditorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease
Diabetic kidney disease (DKD) is a global health problem and is an important risk factor for kidney failure and cardiovascular (CV) disease (Alicic et al., 2017). Until recently, renin angiotensin-aldosterone system inhibitors (RAASi) were the only available agents with proven renoprotective benefit (Brenner et al., 2001;Lewis et al., 2001). In 2019, sodium glucose co-transporter-2 inhibitors (SGLT-2i) revolutionized the management of DKD with added cardiovascular and renal benefits (Perkovic et al., 2019;Heerspink et al., 2020;EMPA-KIDNEY Collaborative Group, 2023). The last few years have been promising with the discovery of newer therapies in DKD targeting diverse pathophysiologic pathways (Heerspink et al., 2019;Bakris et al., 2020;Perkovic et al., 2024). Despite these existing therapies, there is a substantial residual risk of kidney disease progression (Figure 1).The pathogenesis of DKD, though initiated by a metabolic disturbance is perpetuated by multiple interlinked pathways involving the hemodynamic, inflammatory, oxidative, and fibrotic systems (Tuttle et al., 2022). This Research Topic aims to understand these complex mechanisms, identify newer therapeutic targets, and test these agents in well designed clinical trials. Eight articles were published in this Research Topic [retrospective studies (2), animal studies (2), meta-analysis (2), clinical trial (1), and in-depth review (1)]. The in-depth review by Zhang et al., summarizes the proposed mechanisms of albuminuria, the current progress, and the future directions of therapeutic avenues in DKD.Current practice guidelines recommend withholding SGLT-2i during critical illness requiring hospitalization ("sick day rules") (Watson et al., 2023). However, in a multicenter retrospective cohort study of adults hospitalized with acute heart failure associated AKI, exposure to SGLT-2i during AKI was associated with no difference in time to renal recovery, but a lower 30-day mortality (Aklilu et al., 2023). Whether these findings can be generalized to all other etiologies of AKI is unknown. In this Research Topic, Alcantar-Vallin et al. explore the role of continuing or initiating SGLT-2i during an AKI episode. This was a retrospective cohort study involving 374 patients hospitalized with AKI, of whom 58 received SGLT-2i treatment during the hospitalization. The authors found that SGLT-2i use was not associated with risk of major adverse kidney events but was associated with a reduced risk of mortality (OR 0.08, 95% CI 0.01-0.64).In the FLOW trial, semaglutide, a glucagon like peptide-1 receptor agonist (GLP-1Ra) was shown to decrease clinically relevant kidney outcomes and death from CV causes in patients with type 2 diabetes and CKD (Perkovic et al., 2024). In a post hoc analysis of this trial, the benefits of semaglutide in reducing kidney outcomes were found to be consistent in participants with and without SGLT-2i use (Mann et al., 2024). In this Research Topic Cao et al. carried out a head-to-head comparison of GLP-1Ra and SGLT-2i in patients with DKD. This was a randomized, open-label, non-inferiority trial. A total of 106 patients with type 2 diabetes and CKD were randomized 1:1 to receive either polyethylene glycol loxenatide (PEG-Loxe) 0.2 mg subcutaneous once weekly or dapagliflozin 10 mg orally once daily for 24 weeks. The primary outcome was change in urine albumin creatinine ratio (UACR) from baseline to 24 weeks. The authors showed that following 24 weeks of treatment there was no difference in change in UACR between the two groups (mean intergroup difference 1.7% (95% CI, -3 to 6.5%, p=0.380).Diabetes is a state of oxidative stress and inflammatory burden, which contributes to complications including diabetic nephropathy. The heightened oxidative stress in diabetes is multi-factorial, viz., activation of polyol and hexosamine pathways, accumulation of glycolysis intermediates, activation of protein kinase C, mitochondrial dysfunction, etc. (Jin et al., 2023). There is a strong mutually enhancing interaction between inflammation and oxidative stress. Pro-inflammatory cytokines and chemokines activate reactive oxygen species (ROS) leading to macrophage activation, resulting in more oxidative stress. In return, ROS induce the expression of pro-inflammatory cytokines by activating transcription factors like nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1) (Caturano et al., 2023). Hence addressing oxidative stress and inflammation as potential therapeutic targets for DKD have assumed greater significance (Winiarska et al., 2021). In recent years, Chinese herbal medicines have been reported to attenuate progression of DKD by their anti-inflammatory and anti-oxidative properties (Zhong et al., 2015). Chen et al. identified 16 potentially renoprotective Chinese herbal medicines for DKD (PRCHMDKD) which were known to target multiple oxidative stress pathways. The authors then retrospectively analyzed the National Health Insurance Database of Taiwan from 2000 to 2017. They identified 43,480 PRCHMDKD users with DKD and 1,442 PRCHMDKD users with advanced DKD who were matched with an equal number of non-users using a nearest neighbour approach. PRCHMDKD use was associated with reduction in adjusted hazard ratios for kidney failure, all-cause-and CV mortality in the overall and advanced DKD population.Huangkui capsule (HKC) is a traditional Chinese medicine which is currently approved for treatment of CKD in China. It is made from an ethanol extract of Abelmoschus Manihot flowers (Li et al., 2021). In a multicentre, double blind, placebo-controlled randomized clinical trial (RCT) conducted in China, the combination of irbesartan + HKC was found to significantly reduce albuminuria at 24 weeks as compared to irbesartan alone (Zhao et al., 2022). In this Research Topic, Tan et al. carried out a systematic review and meta-analysis of English and Chinese databases to include RCTs comparing HKC combined with RAASi...
- Open Access
- 29 June 2024
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 35 (2) , 243-252
Impact of Noncommunicable Diseases and Heat Stress on Estimated Glomerular Filtration Rate in Security Officers at a Tertiary Care Hospital in South India
Background: The job profile of security officers in tropical countries involves prolonged standing in hot conditions causing heat stress as well as complications of sedentary lifestyle. The objectives of this study were to estimate the prevalence of noncommunicable diseases and heat stress in security officers and analyze factors affecting heat stress and estimated glomerular filtration rate (eGFR). Materials and Methods: This was an observational cross-sectional study conducted among security personnel working at a tertiary care hospital in South India during the hottest months of March to May 2020. Screening camps were conducted during which anthropometric measurements were taken and blood was collected for hemoglobin, creatinine, and fasting glucose estimation. Urine dipstick analysis for glucose, protein, pH, and red and white blood cells were done on early morning voided sample. Heat stress was assessed by a validated 18-item questionnaire called heat strain score index (HSSI). A structured questionnaire was prepared for surveillance of risk factors of noncommunicable diseases. Results: A total of 678 security officers were screened. Majority (659/678, 97.2%) were men and mean age of the cohort was 45.4 ± 9.2 years. Fifty-two percent (355/678) of participants were engaged in outdoor work for a median duration of 6 (IQR, 0-8) hours/day. Prevalence of obesity, diabetes, hypertension, and chronic kidney disease (CKD) were 70.9, 25.5, 15.9 and 1.3 percentage, respectively. Half of the cohort (324/678) had definite heat stress and 0.9% (6/678) developed CKD of undetermined etiology. Heat stress was higher in those working outdoors and longer employment duration and lower in those with abdominal obesity. eGFR was lower in older officers, smokers, hypertensives, and those with longer employment duration, but was unaffected by HSSI scores. Conclusion: Kidney function was unaffected by high levels of heat stress experienced by security personnel working at a tertiary hospital in South India. Future studies are needed to understand the pathomechanisms of differential impacts of heat stress on kidney function of agricultural various worker categories.
- 29 June 2024
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 35 (2) , 243-252
Open AccessImpact of Noncommunicable Diseases and Heat Stress on Estimated Glomerular Filtration Rate in Security Officers at a Tertiary Care Hospital in South India
Background: The job profile of security officers in tropical countries involves prolonged standing in hot conditions causing heat stress as well as complications of sedentary lifestyle. The objectives of this study were to estimate the prevalence of noncommunicable diseases and heat stress in security officers and analyze factors affecting heat stress and estimated glomerular filtration rate (eGFR). Materials and Methods: This was an observational cross-sectional study conducted among security personnel working at a tertiary care hospital in South India during the hottest months of March to May 2020. Screening camps were conducted during which anthropometric measurements were taken and blood was collected for hemoglobin, creatinine, and fasting glucose estimation. Urine dipstick analysis for glucose, protein, pH, and red and white blood cells were done on early morning voided sample. Heat stress was assessed by a validated 18-item questionnaire called heat strain score index (HSSI). A structured questionnaire was prepared for surveillance of risk factors of noncommunicable diseases. Results: A total of 678 security officers were screened. Majority (659/678, 97.2%) were men and mean age of the cohort was 45.4 ± 9.2 years. Fifty-two percent (355/678) of participants were engaged in outdoor work for a median duration of 6 (IQR, 0-8) hours/day. Prevalence of obesity, diabetes, hypertension, and chronic kidney disease (CKD) were 70.9, 25.5, 15.9 and 1.3 percentage, respectively. Half of the cohort (324/678) had definite heat stress and 0.9% (6/678) developed CKD of undetermined etiology. Heat stress was higher in those working outdoors and longer employment duration and lower in those with abdominal obesity. eGFR was lower in older officers, smokers, hypertensives, and those with longer employment duration, but was unaffected by HSSI scores. Conclusion: Kidney function was unaffected by high levels of heat stress experienced by security personnel working at a tertiary hospital in South India. Future studies are needed to understand the pathomechanisms of differential impacts of heat stress on kidney function of agricultural various worker categories.
- Open Access
- 26 July 2023
- Published by Wiley in Nephrology
- Vol. 28 (11) , 597-610
Bacterial infection‐related glomerulonephritis in patients with diabetes
Aim: Diabetic patients are prone to infections, thus making them a unique cohort at risk of developing bacterial infection‐related glomerulonephritis (IRGN).Methods: In total, 1693 adult diabetic patients underwent kidney biopsy between 2005 and 2021 at our tertiary care hospital in South India. Of these, 121 consecutive cases which met criteria of bacterial IRGN were included in this study.Results: The mean age of the cohort was 53.1 ± 10.1 years and 83/121 (68.5%) were males. Majority (98.3%) had type 2 diabetes for a median duration of 6 (IQR, 2–12) years. The most common sites of infection were skin (47/121, 38.8%) and urinary tract (15/121, 12.4%). Fifty percent (58/121) of patients had underlying advanced diabetic kidney disease (DKD). Isolated C3 deposits (without immunoglobulin) occurred in 66/121 (54.5%) patients predominantly in advanced DKD patients. IgA‐dominant glomerulonephritis occurred in only 9/121 (7.4%) patients. Short‐course oral steroid was given to 86/121 (71.1%) patients. Steroid related dysglycemia and immunosuppression related infections occurred in 9/61 (14.8%) and 16/61 (26.2%) patients respectively. Of the 90 patients with follow up details >3 months, 46 (51.1%) progressed to kidney failure over a median period of 0.5 (IQR, 0–7.2) months. Patients diagnosed in the latter half of our study period (2013–2021) were older, less commonly presented with fever, had more pronounced hypocomplementemia and severe renal histology predominantly with a ‘starry sky’ immunofluorescence pattern.Conclusion: Superimposed bacterial IRGN on underlying DKD is associated with poor renal outcomes. Use of short course steroid was associated with significant toxicity.
- 26 July 2023
- Published by Wiley in Nephrology
- Vol. 28 (11) , 597-610
Open AccessBacterial infection‐related glomerulonephritis in patients with diabetes
Aim: Diabetic patients are prone to infections, thus making them a unique cohort at risk of developing bacterial infection‐related glomerulonephritis (IRGN).Methods: In total, 1693 adult diabetic patients underwent kidney biopsy between 2005 and 2021 at our tertiary care hospital in South India. Of these, 121 consecutive cases which met criteria of bacterial IRGN were included in this study.Results: The mean age of the cohort was 53.1 ± 10.1 years and 83/121 (68.5%) were males. Majority (98.3%) had type 2 diabetes for a median duration of 6 (IQR, 2–12) years. The most common sites of infection were skin (47/121, 38.8%) and urinary tract (15/121, 12.4%). Fifty percent (58/121) of patients had underlying advanced diabetic kidney disease (DKD). Isolated C3 deposits (without immunoglobulin) occurred in 66/121 (54.5%) patients predominantly in advanced DKD patients. IgA‐dominant glomerulonephritis occurred in only 9/121 (7.4%) patients. Short‐course oral steroid was given to 86/121 (71.1%) patients. Steroid related dysglycemia and immunosuppression related infections occurred in 9/61 (14.8%) and 16/61 (26.2%) patients respectively. Of the 90 patients with follow up details >3 months, 46 (51.1%) progressed to kidney failure over a median period of 0.5 (IQR, 0–7.2) months. Patients diagnosed in the latter half of our study period (2013–2021) were older, less commonly presented with fever, had more pronounced hypocomplementemia and severe renal histology predominantly with a ‘starry sky’ immunofluorescence pattern.Conclusion: Superimposed bacterial IRGN on underlying DKD is associated with poor renal outcomes. Use of short course steroid was associated with significant toxicity.
- Open Access
- 14 March 2023
- Published by S. Karger AG in Glomerular Diseases
- Vol. 3 (1) , 98-115
Patterns of Renal Dysfunction and Profile of Kidney Biopsies in Hematopoietic Stem Cell Transplant Recipients
Introduction: Post hematopoietic stem cell transplant (HSCT), kidney can be subjected to injury by various causes. Of these, graft versus host disease (GvHD) affecting the kidney is an under-recognized entity with no clear guidelines on its diagnosis, clinicopathological manifestations, and outcomes. Material and Methods: Out of 2,930 patients who underwent HSCT at our center between 2005 and 2020, kidney biopsy was performed in 19 allogenic and 5 autologous recipients. Results: The mean age of the cohort at transplant was 33.2 ± 7 years, and 15 (62%) were males. Median time to kidney biopsy from HSCT was 14 (IQR, 9–30) months. Aplastic anemia was the most common underlying hematological disease (54.2%). All 19 allogenic recipients were classified based on clinicopathological manifestations into either thrombotic microangiopathy (TMA, 12/19 [63%]) or nephrotic syndrome (NS, 7/19 [37%]) pattern. Glomerular tuft “mesangiolysis” was the dominant pattern of injury noted in 9/12 cases of TMA pattern. There was a predominance of acute microangiopathic changes restricted primarily to the glomerular compartment. Of the 7 patients with NS pattern, membranous nephropathy was seen in 4 (57%) and minimal change disease in 3 (43%) patients. Thirty-nine percent (7/18) stained positive for C4d which was predominantly glomerular. Allogenic recipients who did not receive immunosuppression (IS) for renal disease had a lower eGFR at biopsy, a longer latency between withdrawal of GvHD prophylaxis and biopsy, and were significantly at a higher risk of kidney failure (IS: 2/11, 18.1% vs. no IS: 2/6, 33.3%, p = 0.04). “Associated extra-renal GvHD” occurred in 11/19 (57.9%) allogenic recipients. Patients with “associated extra-renal GvHD” had significantly more deaths (6/11, 60% vs. 0, p = 0.02) but comparable renal outcomes. Conclusion: Renal GvHD can present with or without “associated extra-renal GvHD” after a prolonged period of withdrawal of GvHD prophylaxis, requiring careful diagnostic vigilance and consideration of IS.
- 14 March 2023
- Published by S. Karger AG in Glomerular Diseases
- Vol. 3 (1) , 98-115
Open AccessPatterns of Renal Dysfunction and Profile of Kidney Biopsies in Hematopoietic Stem Cell Transplant Recipients
Introduction: Post hematopoietic stem cell transplant (HSCT), kidney can be subjected to injury by various causes. Of these, graft versus host disease (GvHD) affecting the kidney is an under-recognized entity with no clear guidelines on its diagnosis, clinicopathological manifestations, and outcomes. Material and Methods: Out of 2,930 patients who underwent HSCT at our center between 2005 and 2020, kidney biopsy was performed in 19 allogenic and 5 autologous recipients. Results: The mean age of the cohort at transplant was 33.2 ± 7 years, and 15 (62%) were males. Median time to kidney biopsy from HSCT was 14 (IQR, 9–30) months. Aplastic anemia was the most common underlying hematological disease (54.2%). All 19 allogenic recipients were classified based on clinicopathological manifestations into either thrombotic microangiopathy (TMA, 12/19 [63%]) or nephrotic syndrome (NS, 7/19 [37%]) pattern. Glomerular tuft “mesangiolysis” was the dominant pattern of injury noted in 9/12 cases of TMA pattern. There was a predominance of acute microangiopathic changes restricted primarily to the glomerular compartment. Of the 7 patients with NS pattern, membranous nephropathy was seen in 4 (57%) and minimal change disease in 3 (43%) patients. Thirty-nine percent (7/18) stained positive for C4d which was predominantly glomerular. Allogenic recipients who did not receive immunosuppression (IS) for renal disease had a lower eGFR at biopsy, a longer latency between withdrawal of GvHD prophylaxis and biopsy, and were significantly at a higher risk of kidney failure (IS: 2/11, 18.1% vs. no IS: 2/6, 33.3%, p = 0.04). “Associated extra-renal GvHD” occurred in 11/19 (57.9%) allogenic recipients. Patients with “associated extra-renal GvHD” had significantly more deaths (6/11, 60% vs. 0, p = 0.02) but comparable renal outcomes. Conclusion: Renal GvHD can present with or without “associated extra-renal GvHD” after a prolonged period of withdrawal of GvHD prophylaxis, requiring careful diagnostic vigilance and consideration of IS.
- Open Access
- 24 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28335
Predictors of Short-Term Outcomes in Living Donor Renal Allograft Recipients: A Prospective Study From a Tertiary Care Center in North India
Renal transplantation is the optimal treatment for patients of all ages with end-stage kidney disease. The long-term outcomes of renal transplantation are assessed by graft and patient survival rates. These outcomes are, in turn, influenced by post-transplant events such as delayed graft function, rejections, post-transplant infections, and post-transplant diabetes mellitus (PTDM). Each of these short-term outcomes is, in turn, determined by the interplay of various factors in the pre-, peri-, and post-transplant period. This prospective study was designed to understand the factors affecting short-term outcomes in living donor transplantation and their effect on graft and patient survival. A total of 86 patients underwent live donor renal transplantation between January 1, 2015, and March 31, 2016, at a tertiary care hospital in north India. Of these, five were lost to follow-up, and the remaining 81 patients were prospectively followed up to December 31, 2017. The majority of the recipients were males (91%) and the donors were females (74%). Spousal and related donors comprised 49% and 51% of donations, respectively. The mean estimated glomerular filtration rate (eGFR) of donors was 98 ± 9.2 mL/minute/1.73m². Induction therapy with basiliximab was given to 21/81 (26%) recipients. The majority of recipients (68/81, 84%) received triple-drug immunosuppression with prednisolone, tacrolimus, and mycophenolate mofetil. Delayed graft function (DGF) occurred in 4/81 (4.9%) cases. Biopsy-proven acute rejections (BPARs) occurred in 15/81 (18.5%) cases, two-thirds of which were acute antibody-mediated rejections (ABMRs). During the follow-up period, 50 episodes of infections occurred in 35/81 (43.2%) recipients, with the most common being urinary tract infection (23/81, 28.5%). PTDM was diagnosed in 22/81 (27.2%) patients beyond six weeks of transplant. On multivariate logistic regression analysis, the most significant predictor of DGF was acute rejections and vice versa. Acute rejections also predicted the occurrence of post-transplant infections. Pre-transplant hepatitis C virus (HCV) infection and cyclosporine-based therapy were significant predictors of PTDM. At the six-month follow-up, 10/81 (12.3%) patients developed graft dysfunction. The predictors of graft dysfunction at six months were recipients of related donors and rural patients. One-year graft survival, death-censored graft survival, and patient survival rates were 85.2%, 92.6%, and 91.3%, respectively. The most common cause of death was post-transplant infections (5/7, 71.4%) of which the majority (4/5, 80%) were fungal infections. On multivariate logistic regression analysis, the most significant predictor of graft loss and patient loss was low pre-transplant donor eGFR and PTDM, respectively. Graft and patient survival in living donor kidney transplantation are influenced by a multitude of interdependent factors during the pre-transplant (donor eGFR, type of donor, socioeconomic status, HCV infection in recipient, type of immunosuppression) and the post-transplant (DGF, rejections, infections, and PTDM) period.
- 24 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28335
Open AccessPredictors of Short-Term Outcomes in Living Donor Renal Allograft Recipients: A Prospective Study From a Tertiary Care Center in North India
Renal transplantation is the optimal treatment for patients of all ages with end-stage kidney disease. The long-term outcomes of renal transplantation are assessed by graft and patient survival rates. These outcomes are, in turn, influenced by post-transplant events such as delayed graft function, rejections, post-transplant infections, and post-transplant diabetes mellitus (PTDM). Each of these short-term outcomes is, in turn, determined by the interplay of various factors in the pre-, peri-, and post-transplant period. This prospective study was designed to understand the factors affecting short-term outcomes in living donor transplantation and their effect on graft and patient survival. A total of 86 patients underwent live donor renal transplantation between January 1, 2015, and March 31, 2016, at a tertiary care hospital in north India. Of these, five were lost to follow-up, and the remaining 81 patients were prospectively followed up to December 31, 2017. The majority of the recipients were males (91%) and the donors were females (74%). Spousal and related donors comprised 49% and 51% of donations, respectively. The mean estimated glomerular filtration rate (eGFR) of donors was 98 ± 9.2 mL/minute/1.73m². Induction therapy with basiliximab was given to 21/81 (26%) recipients. The majority of recipients (68/81, 84%) received triple-drug immunosuppression with prednisolone, tacrolimus, and mycophenolate mofetil. Delayed graft function (DGF) occurred in 4/81 (4.9%) cases. Biopsy-proven acute rejections (BPARs) occurred in 15/81 (18.5%) cases, two-thirds of which were acute antibody-mediated rejections (ABMRs). During the follow-up period, 50 episodes of infections occurred in 35/81 (43.2%) recipients, with the most common being urinary tract infection (23/81, 28.5%). PTDM was diagnosed in 22/81 (27.2%) patients beyond six weeks of transplant. On multivariate logistic regression analysis, the most significant predictor of DGF was acute rejections and vice versa. Acute rejections also predicted the occurrence of post-transplant infections. Pre-transplant hepatitis C virus (HCV) infection and cyclosporine-based therapy were significant predictors of PTDM. At the six-month follow-up, 10/81 (12.3%) patients developed graft dysfunction. The predictors of graft dysfunction at six months were recipients of related donors and rural patients. One-year graft survival, death-censored graft survival, and patient survival rates were 85.2%, 92.6%, and 91.3%, respectively. The most common cause of death was post-transplant infections (5/7, 71.4%) of which the majority (4/5, 80%) were fungal infections. On multivariate logistic regression analysis, the most significant predictor of graft loss and patient loss was low pre-transplant donor eGFR and PTDM, respectively. Graft and patient survival in living donor kidney transplantation are influenced by a multitude of interdependent factors during the pre-transplant (donor eGFR, type of donor, socioeconomic status, HCV infection in recipient, type of immunosuppression) and the post-transplant (DGF, rejections, infections, and PTDM) period.
- Open Access
- 17 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28091
When to Suspect Non-diabetic Kidney Disease in a Diabetic Patient?
The diagnosis of non-diabetic kidney disease (NDKD) in a diabetic patient has significant therapeutic and prognostic implications. There are certain proven clinical predictors of NDKD, which, when present in an appropriate clinical setting, would warrant a kidney biopsy. Herein, we describe four cases of NDKD diagnosed in rather unusual clinical settings, which add to the list of clinical predictors of NDKD. The first case was a “parainfectious glomerulonephritis” diagnosed in a 50-year-old diabetic woman who presented with persistent renal dysfunction despite successful treatment of urinary tract infection. The second case was “membranous nephropathy” diagnosed in a 43-year-old man with long-standing type 1 diabetes, which was associated with other microvascular complications. In this case, the only predictor was disproportionately low serum albumin. The third case was “amyloid light chain (AL) amyloidosis” diagnosed in an elderly diabetic who presented with progressive anasarca over six months. In this case, the only clinical predictor was a disassociation observed between urine dipstick and 24-hour protein estimation. In the fourth case, an elderly diabetic woman without underlying diabetic retinopathy presented with sudden onset nephrotic syndrome. A kidney biopsy was suggestive of diffuse nodular glomerulosclerosis. Immunofluorescence and electron microscopic evaluation were diagnostic of “gamma heavy chain deposition disease.” In all four cases, diagnosis of NDKD led to major therapeutic changes and attainment of renal remission. We have extensively reviewed all major biopsy cohorts of NDKD and have formulated an approach to the diagnosis of NDKD.
- 17 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28091
Open AccessWhen to Suspect Non-diabetic Kidney Disease in a Diabetic Patient?
The diagnosis of non-diabetic kidney disease (NDKD) in a diabetic patient has significant therapeutic and prognostic implications. There are certain proven clinical predictors of NDKD, which, when present in an appropriate clinical setting, would warrant a kidney biopsy. Herein, we describe four cases of NDKD diagnosed in rather unusual clinical settings, which add to the list of clinical predictors of NDKD. The first case was a “parainfectious glomerulonephritis” diagnosed in a 50-year-old diabetic woman who presented with persistent renal dysfunction despite successful treatment of urinary tract infection. The second case was “membranous nephropathy” diagnosed in a 43-year-old man with long-standing type 1 diabetes, which was associated with other microvascular complications. In this case, the only predictor was disproportionately low serum albumin. The third case was “amyloid light chain (AL) amyloidosis” diagnosed in an elderly diabetic who presented with progressive anasarca over six months. In this case, the only clinical predictor was a disassociation observed between urine dipstick and 24-hour protein estimation. In the fourth case, an elderly diabetic woman without underlying diabetic retinopathy presented with sudden onset nephrotic syndrome. A kidney biopsy was suggestive of diffuse nodular glomerulosclerosis. Immunofluorescence and electron microscopic evaluation were diagnostic of “gamma heavy chain deposition disease.” In all four cases, diagnosis of NDKD led to major therapeutic changes and attainment of renal remission. We have extensively reviewed all major biopsy cohorts of NDKD and have formulated an approach to the diagnosis of NDKD.
- 12 May 2021
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 23 (6) , 877-884
Difficult cannulation of hemodialysis arteriovenous fistula – Role of imaging in access management (DICAF STUDY)
Difficulty in cannulation of arteriovenous fistula (AVF) can lead to inadequate dialysis, transient to permanent loss of access and increases dependency on bridging catheters. This study aimed to analyze the causes for difficult fistula cannulation, using various imaging modalities. This was a retrospective single-center observational study conducted between October 2017 and June 2018. Patients whose fistulae were difficult to cannulate were initially evaluated by physical examination followed by doppler ultrasonography or/and fistulogram as necessary. The patients were divided into two groups that is, primary difficult cannulation (within first three months of creation of fistula) or secondary difficult cannulation (after three months). We encountered difficult cannulation in 43 patients. About 60% were primary difficult cannulations. Most common causes for difficulty in cannulation were cannulation zone (CZ) stenosis (23.3%), immature fistula (20.9%), outflow stenosis (18.6%), inflow stenosis (11.6%), anatomical abnormalities (11.6%), outflow plus CZ stenosis (9.3%) and inflow plus CZ stenosis (4.7%). Among patients with primary difficult cannulation, immature fistula (34.6%) was the most common cause, whereas CZ stenosis (47.1%) was the most common etiology for secondary difficult cannulation. Edema leading to difficult cannulation was found in 12 patients (27.9%), all of which was due to central vein stenosis. Cannulation resulted in hematoma, fistula thrombosis, failure of fistula and pseudoaneurysm in 83.7%, 27.9%, 16.3%, and 2.3% of cases respectively. Bridging temporary dialysis catheter placement was required in 67.4% patients. Ultrasound doppler had lower diagnostic value when compared to fistulogram (71.4% vs 93.9%, p = 0.014). Difficulty in cannulating the arteriovenous fistula is a common problem in hemodialysis patients. We suggest that patients whose fistulae are difficult to cannulate should undergo early radiological evaluation to decrease catheter dependency and access failure.
- 12 May 2021
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 23 (6) , 877-884
Difficult cannulation of hemodialysis arteriovenous fistula – Role of imaging in access management (DICAF STUDY)
Difficulty in cannulation of arteriovenous fistula (AVF) can lead to inadequate dialysis, transient to permanent loss of access and increases dependency on bridging catheters. This study aimed to analyze the causes for difficult fistula cannulation, using various imaging modalities. This was a retrospective single-center observational study conducted between October 2017 and June 2018. Patients whose fistulae were difficult to cannulate were initially evaluated by physical examination followed by doppler ultrasonography or/and fistulogram as necessary. The patients were divided into two groups that is, primary difficult cannulation (within first three months of creation of fistula) or secondary difficult cannulation (after three months). We encountered difficult cannulation in 43 patients. About 60% were primary difficult cannulations. Most common causes for difficulty in cannulation were cannulation zone (CZ) stenosis (23.3%), immature fistula (20.9%), outflow stenosis (18.6%), inflow stenosis (11.6%), anatomical abnormalities (11.6%), outflow plus CZ stenosis (9.3%) and inflow plus CZ stenosis (4.7%). Among patients with primary difficult cannulation, immature fistula (34.6%) was the most common cause, whereas CZ stenosis (47.1%) was the most common etiology for secondary difficult cannulation. Edema leading to difficult cannulation was found in 12 patients (27.9%), all of which was due to central vein stenosis. Cannulation resulted in hematoma, fistula thrombosis, failure of fistula and pseudoaneurysm in 83.7%, 27.9%, 16.3%, and 2.3% of cases respectively. Bridging temporary dialysis catheter placement was required in 67.4% patients. Ultrasound doppler had lower diagnostic value when compared to fistulogram (71.4% vs 93.9%, p = 0.014). Difficulty in cannulating the arteriovenous fistula is a common problem in hemodialysis patients. We suggest that patients whose fistulae are difficult to cannulate should undergo early radiological evaluation to decrease catheter dependency and access failure.
- Open Access
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S60
POS-150 CLINICAL AND HISTOPATHOLOGICAL PROFILE AND OUTCOME OF PATIENTS WITH BIOPSY PROVEN PGNMID (PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITS)
- 1 April 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (4) , S60
Open AccessPOS-150 CLINICAL AND HISTOPATHOLOGICAL PROFILE AND OUTCOME OF PATIENTS WITH BIOPSY PROVEN PGNMID (PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITS)